tapebrief
HUM · Q4 2025

HUM · Q1 2026 Earnings

Cautious

Humana

Reported April 29, 2026

30-second summary

Humana opened FY2026 with Q1 revenue of $39.65B (+23.4% YoY) and adjusted EPS of $10.31, with the Insurance segment benefit ratio at 89.4% — well below the FY guide of 92.75% ±25bps, as expected for Q1 seasonality. The headline guidance change is a $0.53 cut to FY GAAP EPS (to "at least $8.36" from "at least $8.89") attributed to the Bonus Year 2026 Star Ratings headwind net of mitigation; adjusted EPS held at "at least $9.00," MA membership growth held at ~25%, and the Insurance benefit ratio range was held at 92.75% ±25bps. The trade established last quarter — absorb the 2026 trough, build to 2028 on scale and CenterWell — is intact, with the GAAP/non-GAAP gap widening again as the charge stack proves recurring rather than one-time.

Headline numbers

EPS

Q1 FY2026

$10.31

Revenue

Q1 FY2026

$39.65B

+23.4% YoY

Operating margin

Q1 FY2026

4.4%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$39.65B+23.4%$32.52B+21.9%
EPS$10.31—$-3.96+360.4%
Operating margin4.4%———

Guidance

Full-year GAAP EPS guidance cut $0.53 (5.96%) to 'at least $8.36' due to Star Ratings headwind, while Adjusted EPS and MA membership growth remain reaffirmed; company discloses new segment and operating metrics floors for FY2026.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

MetricPeriodGuideYoY
Insurance segment benefit ratioFY 202692.75% +/- 25 bps—
Insurance segment revenueFY 2026at least $155 billion—
CenterWell segment revenueFY 2026at least $25 billion—
Operating cost ratioFY 202610.0% +/- 25 bps—
CenterWell segment income from operations (GAAP)FY 2026$1.3B to $1.8B—
CenterWell segment income from operations (Non-GAAP)FY 2026$1.5B to $2.0B—
RevenueFY 2026at least $160 billion—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
GAAP EPS
FY 2026
at least $8.89at least $8.36-$0.53 below prior guideLowered

Reaffirmed unchanged this quarter: Adjusted (non-GAAP) EPS (at least $9.00), Individual Medicare Advantage membership growth (approximately 25 percent)

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
Insurance Segment$38.059B+23.1%
CenterWell Segment$6.1B+19.8%
Individual Medicare Advantage$28.252B+24.5%
Medicare Stand-alone PDP$2.617B+80.9%
Group Medicare Advantage$2.911B+25.4%
CenterWell Primary Care$1.922B+35.5%
CenterWell Pharmacy Solutions$3.152B+10.8%
CenterWell Home Solutions$1.026B+23.3%

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Insurance Segment Benefit Ratio89.4%
Insurance Segment Operating Cost Ratio7.3%
Consolidated Benefit Ratio89.4%
Consolidated Operating Cost Ratio10.2%
CenterWell Operating Cost Ratio94.5%
Total Medical Membership17,711.4 thousand
Individual Medicare Advantage Membership6,393.3 thousand
Days in Claims Payable33.9 days

Management tone

Q2 2025 cautious bounded confidence → Q3 2025 retention/LTV pivot → Q4 2025 explicit 2026 trough acknowledgment → Q1 2026 disciplined margin-first posture into 2027 bids.

The transcript was not available beyond Q&A excerpts; the tone analysis below is built from the Q&A and the guidance change pattern, not from prepared remarks.

Two quarters ago, management refused to give a 2026 enrollment range. One quarter ago, they fully owned the magnitude of the 2026 trough and reframed around 2028 earnings power. This quarter, they have moved one further: the 2027 bid framework is now articulated explicitly, with margin progression toward the 2028 ≥3% target placed first in a three-priority stack ahead of retention and growth. To Justin Lake, management said the bid approach prioritizes "being on track for 2028 with at least 3% sustainable margin" first, retention second, growth "a distant third" — the most explicit ordering management has given. The shift signals that the 2027 bid season will see further benefit reductions despite member-retention costs.

The framing of the 2027 funding gap as worse than 2026 — confirmed to Kevin Fishbeck — is the second material shift. Three quarters ago, management characterized cost-cutting as the lever; this quarter, they explicitly conceded that the funding gap vs. medical cost trend is "larger going into the 2027 bid season than it was a year ago" with cost initiatives on track and medical cost trend stable for two years. The constraint is being relocated to external (CMS funding) from internal (execution) — which is both honest and a setup for further benefit reductions to be framed as unavoidable.

The Q1 reserving posture confirms operational discipline rather than emerging cost pressure. Management told Anne Hines that IBNR up 35% against 22% membership growth reflects "prudent" reserving given the new-cohort uncertainty, with completed claims and April data running "in line to better than guidance." The reserve build is a credibility deposit ahead of the 2H benefit ratio step-up the FY guide requires.

The shift toward more granular segment-level disclosures this quarter (Insurance benefit ratio range, CenterWell income range, consolidated operating cost ratio range) is itself a tone signal: management is creating more granular benchmarks against which investors can hold them, suggesting confidence that the operational program is tracking — even as the GAAP cut concedes that mitigation is running $0.53 light against three months ago.

Q&A highlights

Justin Lake · Wolf Research

How should investors think about Humana potentially adding cushion to 2027 bids to reflect new member cost uncertainty and the expectation of improved STARS benefit in 2028 (which reduces the TDC), while still protecting 2027 margins?

Management clarified that the bidding approach prioritizes three things in order: (1) being on track for 2028 with at least 3% sustainable margin, which factors in TBC limitations and STARS expectations; (2) retaining members by making thoughtful benefit adjustments that minimize impact on items members value most; (3) growth as a distant third priority. They indicated they are very aware of TBC constraints and what happens when STARS improves, and this is very much part of their 2027 planning process. They emphasized going market-by-market and that the industry is taking a measured approach given the funding environment.

2028 margin target: at least 3% sustainable marginThree bid priorities in order: 2028 on-track, retention, growthManagement is aware of TBC limitations and STARS recovery expectationsMarket-by-market approach to benefit adjustments

Anne Hines · Mizuho

Why did IBNR (Incurred But Not Reported) reserves grow 35% sequentially when total Medicare Advantage membership only grew 22%? Is this conservatism, or did it come in line with expectations?

Management stated they took a prudent approach to claims reserves given how early it is in the year and given the membership growth. They emphasized this is consistent with prudent assumptions embedded in beginning-of-year guidance, which they are maintaining. They feel very good about Q1 indicators and early April data, which are fairly consistent with expectations. All early indicators (completed claims, April data) are running in line to better than guidance.

IBNR up 35% sequentially vs 22% membership growthTaken prudent approach to claims reservesGuidance maintained for the yearEarly indicators (through end of April) in line to better than expectations

Kevin Fishbeck · Bank of America

Why is management saying it will need to cut benefits in 2027 to achieve margin targets when this year they were able to double MA margins without significant benefit changes? Is the 2027 funding shortfall larger than 2026, or is it timing of cost-cutting initiatives?

Management confirmed that the funding gap between CMS rates and medical cost trend is larger going into the 2027 bid season than it was a year ago. While cost management initiatives are on track and medical cost trend has been relatively stable, the funding environment is the primary driver. Management noted they appreciated CMS's help but the funding still doesn't keep pace with trend. They emphasized they will make appropriate benefit adjustments as they have in the past, and they made adjustments earlier than most competitors.

Funding gap vs. medical cost trend is larger in 2027 vs. 2026Medical cost trend stable for two yearsCost management plans on trackHumana made benefit adjustments earlier than industry competitors

AJ Rice · UBS

How much incremental information advantage does Humana have from new monitoring initiatives compared to historical practice? And given the structural positives in 2028 (STARS recovery, TBC impact), is management willing to slow margin progression in 2027 to preserve membership?

Management stated they are not tracking new indicators per se, but rather being more disciplined in looking at existing indicators on a regular cadence to understand trend in real time. They emphasized starting with 'where does margin need to be each year' to be on track for 2028, not with 'how much do we want to grow.' They multi-year plan accounting for different 2028 scenarios. On claims work, they're doing more anomaly detection on the front end (regional, provider, DRG) and deeper analysis on new member components. Early indicators and April claims running in line to better than expected.

More disciplined, regular cadence monitoring of existing indicators (not new metrics)Margin-first principle: determine required margin each year to be on track for 2028Multi-year planning for multiple 2028 scenariosEnhanced front-end claims anomaly detection by region, provider, DRG

Michael Hoff · Baird

Is the 2027 setup for margin improvement actually better than 2025 given stronger rate notice, improving STARS on a year-over-year basis (from diversification), and a similar conservative posture on benefits and pricing, while transformation efforts are now more mature?

Management agreed that transformation efforts are now more mature and stood up, giving broader array of operational levers (G&A cost management, clinical cost management). They have more tailwind operationally compared to two years ago, which provides more levers outside of benefits to close the funding gap. However, they still have to look at both operational levers and benefit changes to achieve target margin. The logic is the same each year: assess funding gap vs. trend, determine what operational actions can close that gap, then make necessary benefit adjustments to reach sustainable margin target.

Transformation efforts more mature and stood up in 2026 vs. 2024Broader array of operational levers available than two years agoG&A and clinical cost management improvements providing tailwindStill need to evaluate both operational levers and benefit changes

Answers to last quarter's watch list

The composition of the FY2025 Q4 GAAP charge stack — the company didn't break out the recurring vs. discrete characterization on the Q1 print. The fact that GAAP EPS guidance was cut by $0.53 (with non-GAAP held flat) while the FY2026 GAAP-to-non-GAAP gap widened suggests the charge stack contains structural items being treated as non-recurring, but no explicit decomposition was provided.
Continue monitoring
Q1 2026 Insurance benefit ratio against the FY2026 build — Q1 benefit ratio printed 89.4%, well below the FY 92.75% ±25bps guide as expected for Q1 seasonality. Management characterized April data as in line to better than guidance and built IBNR up 35% sequentially against 22% membership growth — a prudent reserving posture. The new-cohort cost pressure has not yet shown through; the implied 2H step-up to ~94%+ is the test.
Continue monitoring
2027 advance rate notice response and bid adjustment signaling — management signaled explicit margin-prioritizing bid posture for 2027, with margin progression to ≥3% sustainable by 2028 placed first ahead of retention and growth. They confirmed the funding gap is larger in 2027 than 2026 and that benefit adjustments will be needed. No county-exit specifics. Status: Resolved negatively (further benefit reductions confirmed; member impact unquantified).
CenterWell senior primary care patient adds in Q1 — CenterWell Primary Care revenue grew 35.5% in Q1 — the strongest segment growth on the print, reflecting both The Villages contribution and accelerating organic patient adds. No Q1-specific patient count was disclosed. Status: Continue monitoring (revenue trajectory is positive; margin disclosure on the cohort as it scales remains the open question).
Quantification of the Star Ratings headwind components — the $0.53 GAAP guidance cut was attributed to Star Ratings headwind for Bonus Year 2026 "net of mitigation," but the gross headwind, mitigation magnitude, and 4+ star contract mix were not disclosed this quarter. The $3.5B net headwind sized last quarter remains the only quantitative anchor.
Not resolved
Days in claims payable bottom — DCP rebuilt 2.0 days to 33.9 from the 31.9 trough at Dec 31. This is the first sequential rebuild after several quarters of compression and is consistent with management's prudent reserving posture for the new-member cohort. Status: Resolved positively (rebuild confirmed; IBNR adequacy posture credible).

What to watch into next quarter

2H benefit ratio step-up to the 92.75% ±25bps FY range — with Q1 at 89.4% and management noting April data in line to better than expectations, watch whether the 2H ratio mechanically lands inside the range or whether new-cohort costs force a guide widening. The required 2H exit run-rate is roughly 94%+.

Whether the consolidated operating cost ratio breaches the 10.25% ceiling — Q1 already printed at 10.2%, the upper end of the new FY 10.0% ±25bps guide. There is essentially no room for sequential degradation; watch Q2 for whether transformation-driven G&A leverage starts to pull the ratio down or whether the FY range is revisited.

2027 bid disclosure specifics — by the Q2 print, management should be in active bid submission. Watch for any color on county footprint changes, specific benefit redesigns, or whether the explicit "growth is a distant third" framing translates into a quantified 2027 membership posture.

Resolution of the GAAP/non-GAAP wedge — the $0.64 FY2026 spread (≥$9.00 non-GAAP vs ≥$8.36 GAAP) is meaningfully wider in percentage terms than FY2025. Watch the 10-Q for the explicit decomposition of value creation initiative charges, impairments, and put/call adjustments embedded in the FY GAAP guide.

IBNR adequacy as the new-member cohort ages — the 35% sequential IBNR build is a credibility deposit. Watch Q2 for whether reserves prove adequate (no favorable or adverse PYD) or whether the prudent Q1 posture proves either over- or under-reserved.

Updated quantification of the 2026 Stars headwind — with management citing "net of mitigation" as the GAAP cut driver, watch whether Q2 disclosure breaks out the gross headwind, mitigation magnitude, and the 4+ star contract mix more explicitly than the $3.5B net figure given last quarter.

Sources

  1. Humana Q1 2026 detailed press release (8-K Ex. 99.2): https://www.sec.gov/Archives/edgar/data/49071/000004907126000021/hum-2026q1xex99x2detailedx.htm
  2. Humana Q1 2026 earnings call Q&A excerpts (analyst exchanges with Wolfe Research, Mizuho, Bank of America, UBS, Baird)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.